Pneumococcal Vaccine Uptake in Adults Before and After Hospitalization for Pneumococcal Infections in Hong Kong, 2015 to 2024.

Publication date: May 19, 2025

Background/Objectives: Vaccination is a key preventive measure against pneumococcal disease, but uptake rates remain low in high-risk populations. Limited information exists on pneumococcal vaccine uptake in individuals with a history of pneumococcal disease. This study aims to assess pneumococcal vaccine uptake and the factors associated with it in patients hospitalized for pneumococcal disease, before and after hospitalization, across time periods before, during, and after the COVID-19 pandemic. Methods: Data for patients aged ≥18 years who were hospitalized for pneumococcal disease between 2015 and 2024 were extracted from the Hospital Authority’s territory-wide electronic medical record database. The uptake of pneumococcal vaccines in subgroups aged 18-64 years and ≥65 years, with and without risk conditions, both before and after hospitalization for pneumococcal disease, was assessed, followed by multivariate analyses of the factors associated with vaccination uptake by logistic regression models. Results: This study included 5517 patients hospitalized for pneumococcal disease. Prior to hospitalization, the vaccination uptake among the eligible patients was 20. 5%, with only 8. 1% fully vaccinated, despite the majority (87. 9%) having previous hospitalizations (subgroup medians 3-9 times) or outpatient clinic visits (subgroup median 61-107 times). After discharge, during a median follow-up of 1. 85 years, almost all the eligible patients (98. 4%) received subsequent inpatient (subgroup medians 3-4 times) and outpatient (subgroup medians 21-28 times) care, but only 32. 2% of the eligible patients received the vaccine. Factors associated with increased vaccine uptake post-discharge included age ≥75 years (OR 1. 6), ≥10 subsequent hospitalizations (OR 2. 1), and ≥10 subsequent clinic visits (OR 55. 9). Vaccination rates within 12 months post-discharge were significantly lower in the patients hospitalized during the COVID-19 pandemic (3. 5%) compared to the baseline (11. 6%) and post-COVID-19 (6. 6%) periods. Conclusions: The uptake of the pneumococcal vaccine before hospitalization for pneumococcal disease was low and continued to be suboptimal post-discharge. Numerous vaccination opportunities were missed in both the inpatient and outpatient settings. These findings indicate a need to improve vaccination strategies.

Open Access PDF

Concepts Keywords
Basel hospitalization
Outpatient pneumococcal disease
Pandemic pneumococcal vaccines
Vaccinated vaccine uptake

Semantics

Type Source Name
disease MESH Pneumococcal Infections
disease IDO history
disease MESH COVID-19 pandemic
disease MESH Infection
disease MESH pneumococcal pneumonia
disease MESH morbidity
drug DRUGBANK Penciclovir
disease MESH recurrence
disease MESH pneumonia
disease MESH Vaccine Preventable Diseases
disease MESH cardiovascular diseases
disease MESH myocardial infarction
disease MESH heart failure
disease MESH chronic obstructive pulmonary disease
disease MESH liver cirrhosis
disease MESH liver failure
disease MESH chronic kidney disease
disease MESH diabetes mellitus
disease MESH malignancy
disease IDO immunodeficiency
disease MESH hemiplegia
disease MESH stroke

Original Article

(Visited 1 times, 1 visits today)